MEF2C and acute myeloid leukemia: MEF2C, a known downstream target of ERK5 [82,141], has recently been shown to be involved in 1,25D-induced AML differentiation and is reported to lie upstream of C/EBPβ and to control the expression of CD14, but not CD11b [176].